In conclusion, this study revealed that RUNX1 plays an essential role in the development of replacement pattern vessel co-opting CRCLM lesions through regulation of its downstream molecules including ARP2/3, vimentin, and TSP1, which facilitate cancer cell motility. Here, ACTR2 is linked to cancer.